Fifth Third Wealth Advisors LLC Reduces Stock Position in Abbott Laboratories $ABT

Fifth Third Wealth Advisors LLC decreased its holdings in Abbott Laboratories (NYSE:ABT) by 14.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,476 shares of the healthcare product maker’s stock after selling 7,824 shares during the period. Fifth Third Wealth Advisors LLC’s holdings in Abbott Laboratories were worth $4,669,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Freemont Management S.A. grew its position in shares of Abbott Laboratories by 197.2% during the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock worth $1,341,000 after buying an additional 7,100 shares in the last quarter. PFA Pension Forsikringsaktieselskab bought a new stake in shares of Abbott Laboratories in the fourth quarter valued at about $116,580,000. Thrivent Financial for Lutherans lifted its stake in Abbott Laboratories by 24.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock worth $30,931,000 after acquiring an additional 48,286 shares during the period. Danica Pension Livsforsikringsaktieselskab purchased a new stake in Abbott Laboratories in the third quarter worth about $185,640,000. Finally, Net Worth Advisory Group bought a new position in Abbott Laboratories during the 4th quarter worth about $1,366,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Trading Down 0.1%

NYSE ABT opened at $90.46 on Thursday. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $138.84. The company has a 50 day moving average price of $89.39 and a 200 day moving average price of $105.69. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The firm has a market cap of $157.56 billion, a PE ratio of 25.34, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. Abbott Laboratories’s revenue was up 7.8% compared to the same quarter last year. During the same period last year, the firm earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.8%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s payout ratio is 70.59%.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau purchased 2,200 shares of the company’s stock in a transaction dated Thursday, April 23rd. The shares were acquired at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the purchase, the chief financial officer owned 2,200 shares of the company’s stock, valued at approximately $201,300. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Wells Fargo & Company lowered their price target on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Bank of America cut their price objective on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. UBS Group lowered their target price on Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating for the company in a report on Monday, April 20th. Raymond James Financial dropped their target price on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Finally, Oppenheimer reduced their price target on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $118.30.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott signed a global licensing agreement with ALZpath to incorporate its pTau217 antibody into a blood-based Alzheimer’s diagnostic, a potentially meaningful addition to Abbott’s diagnostics portfolio. Reuters article
• Positive Sentiment: Reports highlighted growing momentum in Abbott’s emerging markets and EPD business, supported by branded generics demand, biosimilar expansion, and new approvals, which points to continued international growth. Article
• Positive Sentiment: MiniMed’s launch of Abbott Instinct sensors across European markets expands Abbott’s diabetes technology reach and reinforces the company’s connected care ecosystem. Article
• Positive Sentiment: Abbott was also featured in bullish commentary as a durable dividend aristocrat with 54 straight years of dividend increases, which may be supporting investor sentiment around the stock. Article
• Neutral Sentiment: Abbott continued to draw investor and analyst attention, with articles noting strong interest and a “Moderate Buy” consensus, but these are more sentiment indicators than new fundamental developments. Zacks article
• Negative Sentiment: A Missouri appeals court decision allowing Abbott’s $495 million preterm baby formula verdict appeal to remain in place keeps a major legal overhang on the shares. Article

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.